Claims
- 1. N-(2,3-Epoxypropyl)4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine and its pharmaceutically acceptable acid addition salts.
- 2. 1-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-2-propanone and its pharmaceutically acceptable acid addition salts.
- 3. 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]-2-hydroxyethanone and its pharmaceutically acceptable acid addition salts.
- 4. A pharmaceuticlal composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3.
- 5. A depot pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 3 wherein the compound contains a hydroxy group which has been acylated.
- 6. The depot pharmaceutical composition of claim 5, wherein the hydroxy group is acylated with a (C4-C18)alkanoyl group or a (C4-C18)alkoxycarbonyl group.
- 7. The depot pharmaceutical composition of claim 5 which contains a pharmaceutically acceptable oil.
- 8. The depot pharmaceutical composition of claim 7, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil and esters of fatty acids and polyfunctional alcohols.
- 9. The depot pharmaceutical composition of claim 6 which contains a pharmaceutically acceptable oil.
- 10. The depot pharmaceutical composition of claim 9, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cotton seed oil, corn oil, soybean oil, olive oil and esters of fatty acids and polyfunctional alcohols.
- 11. A method for providing a long acting antipsychotic effect which comprises injecting into a mammal an amount of the composition of claim 5 sufficient to produce a long acting antipsychotic effect.
- 12. An antipsychotic composition which comprises the compound of claim 3 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 13. A method of treating psychoses which comprises administering to a mammal a psychoses-treating amount of a compound of claim 3.
- 14. An antipsychotic composition which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 15. A method of treating psychoses which comprises administering to a mammal a psychoses-treating amount of a compound of claim 1.
- 16. An antipsychotic composition which comprises the compound of claim 2 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier.
- 17. A method of treating psychoses which comprises administering to a mammal a psychoses-treating amount of a compound of claim 2.
CROSS REFERENCE TO RELATED APPLICATION
This is a division of application Ser. No. 08/468,611, filed Jun. 6, 1995, now U.S. Pat. No. 6,140,345, which is a division of Ser. No. 08/329,000, filed Oct. 25, 1994, now U.S. Pat. No. 5,776,963, which is a CIP of Ser. No. 08/144,265, filed Oct. 28, 1993, now abandoned. The entire disclosure of these applications is relied upon and incorporated by reference herein.
US Referenced Citations (14)
Number |
Name |
Date |
Kind |
3950527 |
Derible et al. |
Apr 1976 |
A |
4355037 |
Strupczewski et al. |
Oct 1982 |
A |
4458076 |
Strupczewski |
Jul 1984 |
A |
4590196 |
Smith et al. |
May 1986 |
A |
4670447 |
Strupczewski et al. |
Jun 1987 |
A |
4745117 |
Ishizumi et al. |
May 1988 |
A |
4780466 |
Hrib et al. |
Oct 1988 |
A |
4880930 |
New |
Nov 1989 |
A |
4937249 |
Antoku et al. |
Jun 1990 |
A |
4954503 |
Strupczewski et al. |
Sep 1990 |
A |
4968792 |
Stack et al. |
Nov 1990 |
A |
4999356 |
Strupczewski et al. |
Mar 1991 |
A |
5001134 |
Ferrand et al. |
Mar 1991 |
A |
5364866 |
Strupczewski et al. |
Nov 1994 |
A |
Foreign Referenced Citations (23)
Number |
Date |
Country |
353 0089 |
Mar 1986 |
DE |
2 503 816 |
Jul 1975 |
DK |
0 261 688 |
Mar 1980 |
EP |
0 013 612 |
Jul 1980 |
EP |
0 135 781 |
Apr 1985 |
EP |
0 196 096 |
Oct 1986 |
EP |
0 302 423 |
Feb 1989 |
EP |
0 314 098 |
May 1989 |
EP |
0 329 168 |
Aug 1989 |
EP |
0 357 134 |
Aug 1989 |
EP |
0 353 821 |
Feb 1990 |
EP |
0 398 425 |
Nov 1990 |
EP |
0 402 644 |
Dec 1990 |
EP |
0 464 846 |
Jan 1992 |
EP |
0 542 136 |
May 1992 |
EP |
2 163 432 |
Feb 1986 |
GB |
233 710 |
May 1990 |
NZ |
233 503 |
Jun 1991 |
NZ |
233 525 |
Sep 1991 |
NZ |
WO 9316703 |
Aug 1985 |
WO |
WO 9309102 |
May 1993 |
WO |
WO 9316073 |
Aug 1993 |
WO |
WO 9418196 |
Aug 1994 |
WO |
Non-Patent Literature Citations (1)
Entry |
Fuller, R. W., Drugs Acting on Serotonergic Neuronal Systems, Biology of Serotonergic Transmission, John Wiley & Sons Ltd., 1982, pp. 221-247. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/144265 |
Oct 1993 |
US |
Child |
08/329000 |
|
US |